A US study of 80 subjects found a statistically significant inverse correlation between mumps titre levels and COVID-19 severity in people under age 42 who have had MMR II vaccinations.
The measles-mumps-rubella (MMR) vaccine has been theorised to provide protection against COVID-19. In a study published in mBio, an open-access journal of the American Society for Microbiology, researchers provide further proof of this by showing that mumps IgG titrez, or levels of IgG antibody, are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with the MMR II vaccine produced by Merck. MMR II contains the Edmonston strain of measles, the Jeryl Lynn (B-level) strain of mumps, and the Wistar RA 27/3 strain of rubella.
"We found a statistically significant inverse correlation between mumps titre levels and COVID-19 severity in people under age 42 who have had MMR II vaccinations," said lead study author Jeffrey E. Gold, president of World Organization, in Georgia. "This adds to other associations demonstrating that the MMR vaccine may be protective against COVID-19. It also may explain why children have a much lower COVID-19 case rate than adults, as well as a much lower death rate. The majority of children get their first MMR vaccination around 12 to 15 months of age and a second one from 4 to 6 years of age."
In the new study, the researchers divided 80 subjects into 2 groups. The MMR II group consisted of 50 US born subjects who would primarily have MMR antibodies from the MMR II vaccine. A comparison group of 30 subjects had no record of MMR II vaccinations, and would primarily have MMR antibodies from other sources, including prior measles, mumps, and/or rubella illnesses. The researchers found a significant inverse correlation (rs = -0.71, P < 0.001) between mumps titres and COVID-19 severity within the MMR II group. There were no significant correlations between mumps titres and disease severity in the comparison group, between mumps titres and age in the MMR II group, or between severity and measles or rubella titres in either group.
Within the MMR II group, mumps titres of 134 to 300 AU/ml (n=8) were only found in those who were functionally immune or asymptomatic. All with mild COVID-19 symptoms had mumps titres below 134 AU/ml (n=17). All with moderate symptoms had mumps titres below 75 AU/ml (n=11). All who had been hospitalised and required oxygen had mumps titres below 32 AU/ml (n=5). Titres were measured by Quest Diagnostics using their standard diagnostic protocol.
"This is the first immunological study to evaluate the relationship between the MMR II vaccine and COVID-19. The statistically significant inverse correlation between mumps titres and COVID-19 indicates that there is a relationship involved that warrants further investigation," said coauthor David J. Hurley, PhD, professor and molecular microbiologist at the University of Georgia. "The MMR II vaccine is considered a safe vaccine with very few side effects. If it has the ultimate benefit of preventing infection from COVID-19, preventing the spread of COVID-19, reducing the severity of it, or a combination of any or all of those, it is a very high reward low risk ratio intervention. Maximum seropositivity is achieved through two vaccinations at least 28 days apart. Based upon our study, it would be prudent to vaccinate those over 40 regardless of whether or not they already have high serum MMR titres."
Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients
Authors: Jeffrey E. Gold, William H. Baumgartl, Ramazan A. Okyay, Warren E. Licht, Paul L. Fidel Jr., Mairi C. Noverr, Larry P. Tilley, David J. Hurley, Balázs Rada, John W. Ashford
Journal date of publication: mBio, November 2020
Abstract
The measles-mumps-rubella (MMR) vaccine has been theorised to provide protection against coronavirus disease 2019 (COVID-19). Our aim was to determine whether any MMR IgG titres are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with MMR II. We divided 80 subjects into two groups, comparing MMR titres to recent COVID-19 severity levels. The MMR II group consisted of 50 subjects who would primarily have MMR antibodies from the MMR II vaccine, and a comparison group of 30 subjects consisted of those who would primarily have MMR antibodies from sources other than MMR II, including prior measles, mumps, and/or rubella illnesses. There was a significant inverse correlation (rs = −0.71, P < 0.001) between mumps virus titres (mumps titres) and COVID-19 severity within the MMR II group. There were no significant correlations between mumps titres and severity in the comparison group, between mumps titres and age in the MMR II group, or between severity and measles or rubella titres in either group. Within the MMR II group, mumps titres of 134 to 300 arbitrary units (AU)/ml (n = 8) were found only in those who were functionally immune or asymptomatic; all with mild symptoms had mumps titres below 134 AU/ml (n = 17); all with moderate symptoms had mumps titres below 75 AU/ml (n = 11); all who had been hospitalised and had required oxygen had mumps vs below 32 AU/ml (n = 5). Our results demonstrate that there is a significant inverse correlation between mumps titres from MMR II and COVID-19 severity.
[link url="https://mbio.asm.org/content/11/6/e02628-20"]mBio study (open access)[/link]